The clinic found some of the highest-risk patients were missing their transition-of-care (TOC) appointments and experiencing 30-day readmissions
doi: 10.1056/NEJMoa2206038 201 ArmstrongMJGauntPAithalGPBartonDHullDParkerRet al
We provide honest, clear information and encourage patients to ask questions for better understanding of their treatment, ensuring complete clarity
doi: 10.1186/s12933-022-01474-z Summary Keywords glucagon-like peptide-1, glucagon-like peptide-1 receptor agonist, cardiovascular diseases, major adverse cardiovascular events, diabetes mellitus Citation Ferhatbegovi L, Mri D and Maci-Dankovi A (2023) The benefits of GLP1 receptors in cardiovascular diseases
In the Phase 2 NEJM trial (2023), participants on 12 mg lost an average of 24.2% of body weight at 48 weeks
A majority of primary care doctors also believe GLP-1s need to be paired with changes in diet and exercise to be effective in driving healthy weight loss